Exicure Q3: $1.2M Cash, Going Concern, Nasdaq Equity Shortfall Before Dec 2 Deadline
XCUR sits 16% above its 52-week low of $0.777.
Summary
Exicure reported $1,225 thousand of cash at September 30, 2026 with substantial doubt about going concern, equity of $1,895 thousand below Nasdaq's minimum ahead of a December 2, 2026 deadline, and a GPC-100 asset sale whose interim payment was missed and is being renegotiated.
Key Events · Earnings and Guidance · XCUR
-
Going Concern With $1.2M Cash
Cash and cash equivalents were $1,225 thousand at September 30, 2026, down from $3,746 thousand at December 31, 2025; management says existing cash will not fund operations for the twelve months after issuance.
-
Nasdaq Equity Deficit Before Deadline
Stockholders' equity of $1,895 thousand is below the $2,500 minimum; Nasdaq's extension runs to December 2, 2026, after which a delisting determination could follow.
-
Q3 Profit Is Non-Cash
Net income of $642 thousand came from a $724 thousand gain on settling the $1,000 milestone with 172,058 shares at $1.60 and a $688 thousand contingent-consideration fair-value gain — no cash inflow.
-
GPC-100 Sale Payment Missed
The KRW 2 billion (~$1,480 thousand) interim payment on the KRW 6.5 billion (~$4,810 thousand) GPCRT asset sale, due November 16, 2026, was not received; the parties are renegotiating price and timing.
Analysis · XCUR · Life Sciences
Exicure ended September with $1,225 thousand of cash, and management states plainly that existing liquidity will not fund operations for the next twelve months — substantial doubt about going concern, with bankruptcy or cessation of operations named as possibilities. Stockholders' equity of $1,895 thousand sits below Nasdaq's $2,500 minimum, and the extension Nasdaq granted on September 10 runs only to December 2, 2026, so a delisting determination is a live near-term risk. The quarter's $642 thousand of net income is accounting, not operations: it comes from a $724 thousand gain on settling the $1,000 Phase 2 milestone with 172,058 shares and a $688 thousand fair-value gain on the contingent consideration liability, both non-cash. The one asset that could change the picture — the GPC-100 sale to GPCRT for KRW 6.5 billion (~$4,810 thousand) — has slipped: the KRW 2 billion (~$1,480 thousand) interim payment due November 16 was not received and the parties are renegotiating price and timing. A newly disclosed material weakness in internal controls adds execution risk on top of the cash problem.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XCUR was trading at $0.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.9M. The 52-week trading range was $0.78 to $9.48. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.